Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Keeping Track: A Glut Of Big Approvals While Lartruvo Makes Its Market Exit

Executive Summary

The latest drug development news and highlights from our US FDA Performance Tracker.

Related Content

Lilly’s Lartruvo Withdrawal Stirs Questions About Payment For Accelerated Approval Drugs
Accelerated Approval Withdrawals Through The Years
US Biosimilars: FDA Seeks To Build On Record Number Of Approvals, But Shutdown May Blunt Progress
Lartruvo Phase III Fail Rocks Lilly Oncology Plans
Keeping Track: Xarelto Earns CV Risk Reduction Claim In Quiet Week; Spotlight On Formal Dispute Resolution
GSK Wins First-Ever Voucher Race With Anti-Malarial Approval
GSK’s Malaria Drug Tafenoquine Heads To US FDA Panel Review With Agency Backing
Erelzi's Disappearing Indications: Biosimilar Loses Two Of Enbrel's Labeling Claims
FDA Bests Annual Novel Drug Approval Record With Four Oks In One Week
Benlysta Is Niche, But Growing, So GSK's Not Giving Up On Lupus


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts